Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II, multicenter, single-arm and open-label study to explore Selinexor in
combination with standard of care R-CHOP in New Diagnosed high-risk GCB-subtype DLBCL (IPI
3-5). Approximately 35 patients plan to be enrolled in about 6-8 study sites of the study.
And the objective is to Evaluate the safety and efficacy of XR-CHOP in High-Risk (IPI 3-5)
GCB-subtype DLBCL.The enrollment period for this study is expected to be approximately 18
months. The study will end when all patients have completed 6 cycles treatment/follow-up
since the initiation of the study drug, or the last patient has expired, has been lost to
follow-up, or has withdrawn consent, whichever occurs first.